Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0G9IU
|
|||
Former ID |
DAP000426
|
|||
Drug Name |
Rifapentine
|
|||
Synonyms |
RIFAPENTINE; Rifapentina; Rifapentinum; Cyclopentylrifampicin; Rifamycin AF/ACPP; Antibiotic DL 473IT; KTC 1; 61379-65-5; MDL 473; DRG-0283; DL 473; R-773; R 77-3; 3-(N-(4-Cyclopentyl-1-piperazinyl)formimidoyl)rifamycin; 3-(4-Cyclopentyl-1-piperazinyl)iminomethylrifamycin SV; 3-(((4-Cyclopentyl-1-piperazinyl)imino)methyl)rifamycin; Rifapentin,(S); NCGC00167431-01; ZINC169621228; NCGC00167431-03; AN-15578; RPE
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Tuberculosis [ICD-11: 1B10-1B1Z; ICD-10: A15-A19, B90] | Approved | [1] | |
Macular degeneration [ICD-11: 9B78.3; ICD-10: H35.3; ICD-9: 362.5] | Investigative | [2] | ||
Therapeutic Class |
Antituberculosis Agents
|
|||
Company |
Sanofi-Aventis
|
|||
Structure |
Download2D MOL
|
|||
Formula |
C47H64N4O12
|
|||
Canonical SMILES |
CC1C=CC=C(C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)C(O4)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)C=NN5CCN(CC5)C6CCCC6)C
|
|||
InChI |
1S/C47H64N4O12/c1-24-13-12-14-25(2)46(59)49-37-32(23-48-51-20-18-50(19-21-51)31-15-10-11-16-31)41(56)34-35(42(37)57)40(55)29(6)44-36(34)45(58)47(8,63-44)61-22-17-33(60-9)26(3)43(62-30(7)52)28(5)39(54)27(4)38(24)53/h12-14,17,22-24,26-28,31,33,38-39,43,53-57H,10-11,15-16,18-21H2,1-9H3,(H,49,59)/b13-12+,22-17+,25-14-,48-23+/t24-,26+,27+,28+,33-,38-,39+,43+,47-/m0/s1
|
|||
InChIKey |
WDZCUPBHRAEYDL-GZAUEHORSA-N
|
|||
CAS Number |
CAS 61379-65-5
|
|||
PubChem Compound ID | ||||
PubChem Substance ID |
10259, 602920, 7847943, 7890313, 12012718, 14865299, 26697128, 46507322, 53787525, 57365631, 74986831, 103630897, 104253363, 119526516, 124757481, 124766243, 125164285, 126592919, 126670697, 134337722, 135005384, 152343627, 160964534, 162175338, 175268349, 175611872, 187072496, 198993633, 219812063, 223676180
|
|||
ChEBI ID |
CHEBI:45304
|
|||
ADReCS Drug ID | BADD_D01937 | |||
SuperDrug ATC ID |
J04AB05
|
|||
SuperDrug CAS ID |
cas=061379655
|
Interaction between the Drug and Microbe | Top | |||
---|---|---|---|---|
The Abundace of Studied Microbe(s) Regulated by Drug | ||||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
Studied Microbe: Bacteroides caccae
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Bacteroides caccae was decreased by Rifapentine (adjusted p-values: 5.04E-06). | |||
Studied Microbe: Bacteroides fragilis enterotoxigenic
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Bacteroides fragilis enterotoxigenic was decreased by Rifapentine (adjusted p-values: 5.85E-06). | |||
Studied Microbe: Bacteroides fragilis nontoxigenic
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Bacteroides fragilis nontoxigenic was decreased by Rifapentine (adjusted p-values: 6.71E-06). | |||
Studied Microbe: Bacteroides ovatus
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Bacteroides ovatus was decreased by Rifapentine (adjusted p-values: 5.04E-06). | |||
Studied Microbe: Bacteroides thetaiotaomicron
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Bacteroides thetaiotaomicron was decreased by Rifapentine (adjusted p-values: 1.09E-05). | |||
Studied Microbe: Bacteroides uniformis
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Bacteroides uniformis was decreased by Rifapentine (adjusted p-values: 6.45E-07). | |||
Studied Microbe: Bacteroides vulgatus
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Bacteroides vulgatus was decreased by Rifapentine (adjusted p-values: 1.95E-06). | |||
Studied Microbe: Bacteroides xylanisolvens
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Bacteroides xylanisolvens was decreased by Rifapentine (adjusted p-values: 4.93E-07). | |||
Studied Microbe: Odoribacter splanchnicus
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Odoribacter splanchnicus was decreased by Rifapentine (adjusted p-values: 5.04E-06). | |||
Studied Microbe: Parabacteroides distasonis
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Parabacteroides distasonis was decreased by Rifapentine (adjusted p-values: 2.73E-07). | |||
Studied Microbe: Parabacteroides merdae
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Parabacteroides merdae was decreased by Rifapentine (adjusted p-values: 4.93E-07). | |||
Studied Microbe: Prevotella copri
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Prevotella copri was decreased by Rifapentine (adjusted p-values: 3.50E-05). | |||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Bifidobacteriales | ||||
Studied Microbe: Bifidobacterium adolescentis
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Bifidobacterium adolescentis was decreased by Rifapentine (adjusted p-values: 5.04E-06). | |||
Studied Microbe: Bifidobacterium longum
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Bifidobacterium longum was decreased by Rifapentine (adjusted p-values: 5.04E-06). | |||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Coriobacteriales | ||||
Studied Microbe: Collinsella aerofaciens
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Collinsella aerofaciens was decreased by Rifapentine (adjusted p-values: 2.73E-07). | |||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Eggerthellales | ||||
Studied Microbe: Eggerthella lenta
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Eggerthella lenta was decreased by Rifapentine (adjusted p-values: 7.67E-06). | |||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Enterobacterales | ||||
Studied Microbe: Escherichia coli ED1a
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Escherichia coli ED1a was decreased by Rifapentine (adjusted p-values: 5.57E-06). | |||
Studied Microbe: Escherichia coli IAI1
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Escherichia coli IAI1 was decreased by Rifapentine (adjusted p-values: 9.13E-06). | |||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
Studied Microbe: Blautia obeum
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Blautia obeum was decreased by Rifapentine (adjusted p-values: 1.72E-06). | |||
Studied Microbe: Clostridioides difficile
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Clostridioides difficile was decreased by Rifapentine (adjusted p-values: 5.04E-06). | |||
Studied Microbe: Clostridium perfringens
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Clostridium perfringens was decreased by Rifapentine (adjusted p-values: 5.51E-07). | |||
Studied Microbe: Coprococcus comes
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Coprococcus comes was decreased by Rifapentine (adjusted p-values: 5.04E-06). | |||
Studied Microbe: Dorea formicigenerans
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Dorea formicigenerans was decreased by Rifapentine (adjusted p-values: 5.04E-06). | |||
Studied Microbe: Enterocloster bolteae
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Enterocloster bolteae was decreased by Rifapentine (adjusted p-values: 2.46E-05). | |||
Studied Microbe: Eubacterium eligens
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Eubacterium eligens was decreased by Rifapentine (adjusted p-values: 1.77E-05). | |||
Studied Microbe: Eubacterium rectale
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Eubacterium rectale was decreased by Rifapentine (adjusted p-values: 2.63E-04). | |||
Studied Microbe: Lacrimispora saccharolytica
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Lacrimispora saccharolytica was decreased by Rifapentine (adjusted p-values: 5.33E-07). | |||
Studied Microbe: Roseburia hominis
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Roseburia hominis was decreased by Rifapentine (adjusted p-values: 2.45E-05). | |||
Studied Microbe: Roseburia intestinalis
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Roseburia intestinalis was decreased by Rifapentine (adjusted p-values: 1.61E-04). | |||
Studied Microbe: Ruminococcus bromii
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Ruminococcus bromii was decreased by Rifapentine (adjusted p-values: 1.31E-05). | |||
Studied Microbe: Ruminococcus gnavus
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Ruminococcus gnavus was decreased by Rifapentine (adjusted p-values: 1.77E-05). | |||
Studied Microbe: Ruminococcus torques
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Ruminococcus torques was decreased by Rifapentine (adjusted p-values: 2.40E-06). | |||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Lactobacillales | ||||
Studied Microbe: Lactobacillus paracasei
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Lactobacillus paracasei was decreased by Rifapentine (adjusted p-values: 5.51E-07). | |||
Studied Microbe: Streptococcus parasanguinis
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Streptococcus parasanguinis was decreased by Rifapentine (adjusted p-values: 5.51E-07). | |||
Studied Microbe: Streptococcus salivarius
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Streptococcus salivarius was decreased by Rifapentine (adjusted p-values: 1.66E-06). | |||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Veillonellales | ||||
Studied Microbe: Veillonella parvula
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Veillonella parvula was decreased by Rifapentine (adjusted p-values: 5.04E-06). | |||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Verrucomicrobiales | ||||
Studied Microbe: Akkermansia muciniphila
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Akkermansia muciniphila was decreased by Rifapentine (adjusted p-values: 7.03E-07). |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | DNA-directed RNA polymerase (RNAP) | Target Info | Binder | [4] |
References | Top | |||
---|---|---|---|---|
REF 1 | Novel agents in the management of Mycobacterium tuberculosis disease. Curr Med Chem. 2007;14(18):2000-8. | |||
REF 2 | The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954. | |||
REF 3 | Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018 Mar 29;555(7698):623-628. | |||
REF 4 | Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1998 Jul;42(7):1853-7. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.